Initial Treatment Approach for Patients with JAK2 V617F Mutation
Risk Stratification and Treatment Recommendations
- The American Society of Clinical Oncology recommends risk-stratified treatment for patients with JAK2 V617F mutation, with hydroxyurea as the first-line cytoreductive therapy for high-risk patients, combined with low-dose aspirin for all patients without contraindications 1, 2
- High-risk patients, defined as those with age >60 years and/or history of thrombosis, should receive hydroxyurea as first-line cytoreductive therapy 2, 3
- Low-dose aspirin (100mg daily) is recommended for all patients without contraindications to reduce thrombotic risk 1, 2
- Aggressive management of cardiovascular risk factors and smoking cessation are also recommended 1
- For high-risk patients, hydroxyurea should be used to normalize blood counts and resolve symptoms, with caution in young patients (<40 years) due to potential leukemogenic effects 1, 2
- For low-risk patients, cytoreductive therapy is generally not indicated if cardiovascular risk factors are well-controlled, but may be considered if platelet count exceeds 1,500 × 10^9/L 1, 2
Special Considerations
- Interferon-α may be preferred over hydroxyurea in young patients (<40 years), particularly women of childbearing age 4
- Patients with extreme thrombocytosis (>1,500 × 10^9/L) should receive cytoreductive therapy to reduce bleeding risk 1, 2
- Patients with thrombotic events should receive low molecular weight heparin followed by long-term oral anticoagulation (INR 2.0-3.0) 6
Monitoring Response
- Regular complete blood counts should be performed to assess response to therapy and monitor for cytopenias 1, 5
- Response should be evaluated by normalization of blood counts and resolution of disease symptoms 1
Management of Treatment Failure or Intolerance
- Resistance or intolerance to hydroxyurea is defined as need for phlebotomy, uncontrolled myeloproliferation, failure to reduce massive splenomegaly, or cytopenia/unacceptable side effects 4
- Second-line therapy options include anagrelide, interferon-α, and pegylated interferon 1, 2